Aileron Therapeutics Earlier Reported Q3 EPS $(0.28) Misses $(0.23) Estimate

Aileron Therapeutics (NASDAQ:ALRN) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.23) by 21.74 percent. This is a 44 percent increase over losses of $(0.5) per share

Benzinga · 11/07/2019 14:34

Aileron Therapeutics (NASDAQ:ALRN) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.23) by 21.74 percent. This is a 44 percent increase over losses of $(0.5) per share from the same period last year.